Saturday 17 October 2026
Export ROIV’s income statement to Excel — free account
Roivant Sciences Ltd.
ROIV Healthcare Biotechnology
In the quarter to June 2026, revenue fell 33.6%, EPS grew 21.2% and free cash flow fell 30.0%, each against the same quarter a year earlier.
33.53
0.51
−1.50%
Follow ROIV
| Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Dec '20 | Mar '18 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 4 | 5 | 2 | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 1.93 | 0.00 | 0.00 | 0.00 | — | — |
P/S ratio |
2,326.88 | 251.93 | 249.73 | 85.84 | 59.84 | 258.96 | — | — |
Altman Z-Score |
28.31 | 18.08 | 9.65 | 0.99 | 1.34 | 5.24 | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Altman Z″-Score (non-manufacturers) |
18.07 | 26.49 | 19.06 | (2.10) | 1.90 | 3.68 | — | — |
P/Operating CF |
(117.33) | (42.41) | (75.32) | (29.37) | (22.44) | (58.09) | — | — |
P/B ratio |
3.63 | 1.41 | 1.27 | 3.27 | 1.62 | 3.02 | — | — |
Price to Tangible BV |
3.73 | 1.45 | 1.29 | 3.60 | 1.62 | 3.02 | — | — |
EV/Sales |
1,846.48 | 94.86 | 64.71 | 65.27 | 26.38 | 176.49 | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.47 | 0.00 | 0.00 | 0.00 | — | — |
EV/Operating CF |
(20.33) | (3.28) | (2.77) | (4.74) | (2.15) | (7.61) | — | — |
EV/FCF |
(20.11) | (3.27) | (2.76) | (4.67) | (2.10) | (7.53) | — | — |
Quick Ratio |
18.00 | 32.71 | 24.35 | 6.15 | 11.18 | 9.74 | 3.08 | — |
Current Ratio |
18.37 | 33.47 | 25.24 | 6.60 | 11.64 | 9.99 | 3.58 | — |
Net Debt/EBITDA |
8.39 | 4.94 | (1.34) | 1.09 | 1.38 | 1.83 | 3.73 | — |
Debt/Assets |
0.00% | 0.00% | 6.13% | 17.42% | 8.12% | 6.58% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.07 | 0.26 | 0.10 | 0.08 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.01 | 0.02 | 0.02 | 0.02 | 0.00 | — |
Operating CF/Net income |
2.50 | 4.88 | (0.18) | 0.84 | 0.80 | 0.68 | 0.64 | — |
Capex/Depreciation |
(2.45) | (0.33) | (0.06) | (0.67) | (2.94) | 0.00 | — | — |
Interest Coverage |
— | — | 129.31 | (42.02) | (191.97) | — | (11.43) | — |
| (5.72%) | (2.96%) | 107.97% | (55.34%) | (41.45%) | (66.40%) | 0.00% | — | |
| (5.38%) | (2.72%) | 90.49% | (40.57%) | (32.67%) | (53.90%) | (0.19%) | — | |
ROIC |
(32.17%) | (208.81%) | 709.46% | (211.69%) | (448.00%) | (868.68%) | 0.00% | — |
Return on Tangible Assets |
(6.12%) | (3.54%) | 67.11% | (64.47%) | (42.52%) | (40.81%) | (27.12%) | — |
Average Days of Receivables |
34,035.81 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
8,254.38% | 1,894.51% | 1,425.61% | 1,016.59% | 1,126.74% | 3,499.72% | — | — |
Selling, General and Administrative Expense of Revenue |
7,390.63% | 2,035.62% | 1,272.07% | 979.94% | 1,401.86% | 1,092.15% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.02 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
4,190.86% | 994.83% | 610.24% | 355.39% | 1,021.88% | 357.04% | — | — |
Graham Net Nets |
0.25 | 0.65 | 0.73 | 0.19 | 0.48 | 0.27 | — | — |
Graham Number |
0.00 | 0.00 | 31.63 | 0.00 | 0.00 | 0.00 | — | — |
Earnings Yield |
(1.62%) | (2.38%) | 51.77% | (19.51%) | (25.82%) | (14.61%) | — | — |
Free Cash Flow Yield |
(3.95%) | (11.53%) | (9.38%) | (16.27%) | (21.01%) | (9.05%) | — | — |
Revenue per Share |
0.01 | 0.04 | 0.04 | 0.09 | 0.08 | 0.04 | 0.00 | — |
Operating CF per Share |
(1.08) | (1.16) | (0.98) | (1.18) | (1.01) | (0.88) | 0.00 | — |
Capex per Share |
(0.01) | (0.01) | 0.00 | (0.02) | (0.03) | (0.01) | 0.00 | — |
Free Cash Flow per Share |
(1.09) | (1.16) | (0.98) | (1.20) | (1.04) | (0.89) | 0.00 | — |
Cash per Share |
6.19 | 6.74 | 8.29 | 2.35 | 3.08 | 3.39 | 0.03 | — |
Shareholders Equity per Share |
7.63 | 7.15 | 8.23 | 2.26 | 3.04 | 3.24 | 7.75 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
7.63 | 7.15 | 8.23 | 2.26 | 3.04 | 3.24 | 7.75 | — |
Free Cash Flow |
(758.56) | (844.05) | (766.65) | (856.08) | (695.16) | (557.94) | (0.25) | — |
Working Capital |
4,886.14 | 4,850.65 | 6,465.07 | 1,526.14 | 1,962.16 | 1,968.03 | 1.42 | — |
Capital Expenditures |
(8.21) | (4.60) | (1.38) | (12.69) | (17.44) | (5.81) | — | — |
Net Current Asset Value |
4,751.11 | 4,750.32 | 5,957.88 | 1,016.57 | 1,600.34 | 1,636.82 | (12.95) | — |
EV/EBIT |
0.00 | 0.00 | 0.47 | 0.00 | 0.00 | 0.00 | — | — |
Capex to Sales |
0.99 | 0.16 | 0.04 | 0.21 | 0.32 | 0.24 | — | — |
Price to Operating Income |
0.00 | 0.00 | 1.82 | 0.00 | 0.00 | 0.00 | — | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.28 | 1.17 | 1.44 | 0.48 | 0.23 | 0.00 | — | — |
Cash ROIC |
(7.91%) | (8.38%) | (5.73%) | (23.13%) | (16.13%) | (12.85%) | (0.06%) | — |
Accounts Receivable Turnover |
0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Accounts Payable Turnover |
0.06 | 0.05 | 0.06 | 0.36 | 0.33 | 0.00 | — | — |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
5,113.41 | 9,492.00 | 3,202.37 | 1,051.79 | 1,407.85 | 3,646.45 | — | — |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Receivables |
385.12 | — | — | — | — | — | — | — |
Average Payables |
20.85 | 18.86 | 25.93 | 36.21 | 27.57 | — | — | — |
Average Assets |
5,572.81 | 6,329.71 | 4,806.04 | 2,487.37 | 2,587.41 | 1,501.24 | 206.39 | — |
Average Common Equity |
5,239.81 | 5,817.86 | 4,028.06 | 1,823.27 | 2,039.23 | 1,218.68 | — | — |
Columns are period end dates · fundamentals updated 1 Oct 2026